Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now later-stage tilt

Open Angle Glaucoma: later-stage trial registry

8 of 30 indexed Open Angle Glaucoma trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #519 of 28,707 conditions by registered trial count.

30 US clinical trials · 8 currently recruiting · #519 of 28,707 conditions by registered trial count

Open Angle Glaucoma: 30 US clinical trials tracked, 8 recruiting.

Open Angle Glaucoma is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Alcon Research, running 4 of these trials.

Enrollment posture brief

Registry condition open-angle-glaucoma

OPEN 8 | RECR 27% | LATE 15 | EARLY 6 | RANK #519 | SPON 4

Nearest open-share peer: Age-related Macular Degeneration (27% recruiting · 75 trials)

AML60%Acute Myeloid Leukemia40%Open Angle Glaucoma (this)27%Anatomic Stage IA Breast Can26.7%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Open Angle Glaucoma

Open Angle Glaucoma lists 8 open slots (27% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Open Angle Glaucoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Open Angle Glaucoma is recruiting below its size-band peers.

    8 of 30 indexed trials (26.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Open Angle Glaucoma trials is spread across many organizations.

    Alcon Research accounts for 4 of 30 trials (13.3%). 24 distinct sponsors appear on at least one study for this condition label.

  3. Typical Open Angle Glaucoma enrolment sits around 150 participants.

    Median target enrolment is 150 among the 29 trials that report a genuine target (sentinel values excluded). 12 of those (41.4%) plan for fewer than 100 participants.

  4. Open Angle Glaucoma research is mostly interventional.

    24 interventional and 6 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22Phase 311Phase 44

Open and recent trials

30 total, page 1 of 1

RECRUITING 300 participants

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

Barnet Dulaney Perkins Eye Centers

NCT06953349

RECRUITING Phase 1 240 participants

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Amneal Pharmaceuticals

NCT06267274

RECRUITING NA 129 participants

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Sanoculis

NCT06313749

RECRUITING Phase 1 96 participants

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

AbbVie

NCT04499248

RECRUITING Phase 4 70 participants

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Prairie Eye Center

NCT06883123

RECRUITING Phase 4 30 participants

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Mayo Clinic

NCT07325240

RECRUITING Phase 4 20 participants

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Jonathon Myers

NCT07228221

RECRUITING Phase 4 20 participants

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

University of Miami

NCT07217678

ACTIVE NOT RECRUITING Phase 3 489 participants

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Alcon Research

NCT07082816

ACTIVE NOT RECRUITING Phase 3 455 participants

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

AbbVie

NCT03891446

ACTIVE NOT RECRUITING NA 150 participants

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

New World Medical

NCT05280366

ACTIVE NOT RECRUITING Phase 1 36 participants

A Study of PER-001 in Participants With Open-Angle Glaucoma

Perfuse Therapeutics

NCT05822245

COMPLETED 2,597 participants

Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma

Agency for Healthcare Research and Quality (AHRQ)

NCT01645319

COMPLETED Phase 3 756 participants

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Aerie Pharmaceuticals

NCT02207621

COMPLETED Phase 3 708 participants

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Aerie Pharmaceuticals

NCT02558374

COMPLETED Phase 3 696 participants

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Nicox Ophthalmics

NCT04630808

COMPLETED Phase 3 682 participants

Evaluation of Safety and Efficacy of PDP-716

Sun Pharma Advanced Research Company Limited

NCT03450629

COMPLETED Phase 3 528 participants

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Pfizer's Upjohn has merged with Mylan to form Viatris

NCT00277498

COMPLETED Phase 3 420 participants

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Bausch & Lomb Incorporated

NCT01749930

COMPLETED 220 participants

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

Allergan

NCT04647214

COMPLETED Phase 2 201 participants

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research

NCT00691717

COMPLETED Phase 3 161 participants

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

Sun Pharma Advanced Research Company Limited

NCT00945958

COMPLETED Phase 2 123 participants

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

Ono Pharmaceutical Co.

NCT02083289

COMPLETED Phase 3 81 participants

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Alcon Research

NCT00465803

COMPLETED 59 participants

Determinants of Compliance With Glaucoma Therapy

University of Alabama at Birmingham

NCT00362622

COMPLETED 40 participants

Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure

University of Colorado, Denver

NCT01779778

COMPLETED 31 participants

Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics

University of Nebraska

NCT01342406

COMPLETED Phase 1 17 participants

Study of ANX007 in Participants With Primary Open-angle Glaucoma

Annexon

NCT04188015

COMPLETED NA 4 participants

Surgical Treatment of Refractory Open Angle Glaucoma

iScience Interventional Corporation

NCT01212861

COMPLETED Phase 3

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

Alcon Research

NCT00047541

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 11
Phase 4 4

Named interventions

Most-linked intervention names on Open Angle Glaucoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AR-13324 Ophthalmic Solution 0.02% Drug
2 trials
Timolol Drug
2 trials
Latanoprost 0.005% Ophthalmic Solution Drug
2 trials
Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution Drug
2 trials
Placebo Other
2 trials
Brimonidine Tartrate Ophthalmic Solution Drug
1 trials
Brimonidine Tartrate Ophthalmic Suspension Drug
1 trials
Alcon Investigational Agent Drug
1 trials

US sites by state

Facility locations filed on Open Angle Glaucoma trials. A trial with sites in several states counts in each.

California 12 trials
Florida 9 trials
Arizona 7 trials
Texas 6 trials
Georgia 6 trials
Colorado 6 trials
Alabama 5 trials
New York 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Open Angle Glaucoma page

30 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 8 Open Angle Glaucoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Alcon Research sponsors the most Open Angle Glaucoma trials on record, review their full trial history before evaluating a specific study. See Alcon Research's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Open Angle Glaucoma condition card totals 30 registered trials; most-linked intervention AR-13324 Ophthalmic Solution 0.02%; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.